key: cord-0879869-3wugaoki
authors: Nabizadeh, Fardin; Balabandian, Mohammad; Sodeifian, Fatemeh; Rezaei, Negin; Rostami, Mohammad Reza; Moghadasi, Abdorreza Naser
title: Autoimmune encephalitis associated with COVID-19: A systematic review
date: 2022-04-06
journal: Mult Scler Relat Disord
DOI: 10.1016/j.msard.2022.103795
sha: 8821b712f5c11dcdb23330f7d2a58913ade99b84
doc_id: 879869
cord_uid: 3wugaoki

INTRODUCTION: There are increasing reports of COVID-19 related neurological complications which may be due to direct viral invasion, or immune mediated inflammatory diseases such as autoimmune encephalitis and ADEM (acute demyelinating encephalomyelitis). In this study, a systematic review is presented of the reported cases infected by the COVID-19 who were diagnosed with various forms of autoimmune encephalitis. METHODS: The authors searched three databases including PubMed, Scopus, and Web of science for extracting original articles on coronavirus/ COVID-19 and AE. RESULTS: Eighteen articles were considered in this study, including 15 case reports, and three case series with a total of 81 patients. Among the studies, 19 cases were reported with AE including 7 (37%) cases of limbic encephalitis, 5 (26%) patients with anti-N-methyl-D-aspartate (NMDA) receptor encephalitis, 2 (11%) with AE presenting as new-onset refractory status epilepticus (NORSE), 1 (5%) case of steroid-responsive encephalitis, and 4 (21%) cases with an unknown type of AE. CONCLUSION: Our systematic review revealed evidence on AE development in patients infected with the COVID-19. Clinicians should be aware of the possible diagnosis of AE when considering other neurological differential diagnosis in SARS-CoV-2 infected patients.

The novel coronavirus disease appeared for the first time in Wuhan of China in December, 2019 (1). Caused by the SARS-CoV-2 virus (severe acute respiratory syndrome coronavirus 2), it is a member of the family of coronaviruses infecting humans which is responsible for lower respiratory infection and can cause acute respiratory distress syndrome (ARDS) (2, 3) .

According to previous reports, there are confirmed cases with neurological manifestations who developed the disease either via direct attack to the central nervous system (CNS) or via autoimmune processes (4, 5) . New evidence has identified an association between the COVID- 19 and systemic autoimmune diseases like autoimmune hemolytic anemia or one-organ-specific diseases like Guillain-Barre syndrome (6, 7) . Several neurological complications have now been described: encephalitis, meningitis, and cerebrovascular diseases including ischemic stroke and hemorrhage, ADEM, encephalopathy, and myopathy (8) (9) (10) .

In the following, a systematic review can be found of the reported cases who were infected by the COVID-19, and diagnosed with various forms of autoimmune encephalitis (AE).

This systematic review was conducted based on Preferred Reporting for Systematic Review and Meta-Analysis (PRISMA) (11) .

We searched three databases of Pubmed, Scopus, and Web of science for extracting original articles on coronavirus/ COVID-19 and autoimmune encephalitis (AE) on the 1 st of April. The search strategy consisted of keywords including "Autoimmune encephalitis", "Limbic encephalitis", "Anti NMDA", "Anti VGKC", "Anti LGI1", "Anti CASPR2", "Anti AMPA", "Anti GAD65", "Anti GABA", "Anti GABAA", "Anti GABAB", "Anti D2", "Anti Dopamine-2", "Anti DPPX", "Anti Glycine", "Anti GlyR", "Anti Glutamate", "Anti mGluR1", "Anti mGluR5", "Anti amphiphysin", "Anti Neuronal", "Anti CV2", "Anti Ta", "Anti Purkinje", "COVID-19", "Sars-Cov-2", and "coronavirus".

We included the studies have reported the AE related to COVID-19 infection. The studies with other types of encephalitis or unconfirmed cases of autoimmune encephalitis were excluded.

Articles were independently selected by two investigators (M.B and M.R) following two steps.

First, the title and abstract were screened. In the next step, the full texts of the selected studies were reviewed according to eligibility criteria. At the end of each step, any disagreements were resolved by discussing the issue with the third investigator (F.N).

The same reviewers (M.B and M.R) independently extracted the following data manually:

author, year, country, study design, number of patients, mean age, sex, number of AE cases, type of AE, and symptoms.

The quantitative data was represented as percentage or mean ± standard deviation. Studies and results were qualitatively compared.

Our comprehensive literature search yielded a total of 208 articles. After removing duplicates and screening titles and abstracts, 22 reports remained; however, after full text reviews, four studies did not meet the inclusion criteria. Finally, qualitative synthesis was performed on18 studies (Figure1).

Among the included studies, there were 15 case report studies, two case series, and one cohort article with a total of 81 patients. 62.6% of these patients were men. Three studies were multicenter (12) (13) (14) , six from Italy (15) (16) (17) (18) (19) (20) , four from UK (21) (22) (23) (24) , two from USA (5, 25) , one from Mexico (4), one from China (26) , and one from France (27) .

Findings from the studies on the AE are summarized in Table1. Among the included studies, 19 cases were reported with AE, including 7 (37%) cases of limbic encephalitis, 5 (26%) patients with anti-N-methyl-D-aspartate (NMDA) receptor encephalitis, 2 (11%) with AE presenting as new-onset refractory status epilepticus (NORSE), 1 (5%) case of steroid-responsive encephalitis, and 4 (21%) cases with unknown type of AE (Table1, Figure 2 ).

A cohort study from UK reported one case of limbic encephalitis out of 29 COVID-19 cases (23) . Also, there was a case series study reporting two patients with limbic encephalitis among 25 COVID-19 patients (16) . The other cases of limbic encephalitis were reported in four case reports (5, 19, 24) . The patients were more likely to develop acute-onset delirium, altered mental status, status epilepticus, cognitive impairment, aphasia, seizure, focal motor deficits, headache, diaphoresis, palpitation, nausea drowsy, mild confusion, and a brief episode of non-responsivity (Table1). In limbic encephalitis, when measured, no cases of LGI1 or CASPR2 antibodies were found.

Five studies reported cases of Anti-NMDA receptor encephalitis. Among the cases, there was a two-year-old girl with symptoms such as fever, poor sleep, constipation, decreased oral intake, not talking, constant kicking, and thrashing movements of arms and legs (25) . Furthermore, three other cases were patients aged 17, 23, and 50 years old with Anti-NMDA receptor encephalitis (4, 14, 18) . It seems that this type of AE affects younger individuals infected with COVID-19.

These patients were reported with altered behavior and mental status, seizures, insomnia, dyskinesia, refractory status epilepticus, over-familiar attitude, increased psychomotor activity, anxiety, and labile affect (Table1).

Moreover, there were two cases with AE presenting as new-onset refractory status epilepticus (NORSE), both from Italy (15, 17) . The clinical symptoms including convulsive status epilepticus, and generalized myoclonic jerks of axial muscles and face were reported in these patients (Table1). A case report also described a patient with steroid responsive encephalitis after COVID 19 infection (13) . The case was unable to carry out simple orders and presented severe akinetic syndrome, palmomental and glabella reflexes, and nuchal rigidity.

Also, seven other studies reported AE in COVID-19 the patients without mentioning the exact type (12, 22, 26, 27) . All the clinical symptoms of encephalitis in reported cases are detailed in Table1.

Different theories have been postulated to explain the pathophysiology of SARS-CoV-2 CNS invasion. SARS-CoV-2 reaches to CNS through systemic circulating system. The virus cannot easily cross the blood brain barrier (BBB) and invade the CNS (28). However, virus recruits three main strategies to cross the BBB. These mechanisms include transcellular migration, paracellular migration, and Trojan horse (29) .

There is another important mechanism explaining the development of AE in the COVID-19

infection. It has been demonstrated that cytokine-mediated neuroinflammation in response to SARS-CoV-2 infection plays an important role in the pathogenesis of AE (23) . Severe case of COVID-19 infection induces overproduction of inflammatory cytokines, known as cytokine storm (28) . Supportably, patients with a severe condition of COVID-19 show higher levels of inflammatory cytokines such as IL-2R, IL-6, IL-8, IL-10, and TNF-α compared to cases with non-severe COVID-19 condition (30) . Elevated IL-6 which is known as a common feature of the disease during the inflammatory phase can be a linking factor due to its role in facilitating autoantibody production in anti-NMDA-R encephalitis (31) . Overproduction of inflammatory cytokines seems to affect BBB integrity, increase its permeability, and lead to viral transmission through BBB (28) . Furthermore, it has been shown that SARS-CoV-2 induces production of anti-NMDA-R autoantibodies and causes AE (32) . Based on the reviewed articles in this study, hyperinflammation syndrome is a leading cause for the development of AE in the majority of COVID-19 patients. Moreover, the results indicate that the AE is mostly presented several days after respiratory symptoms, suggesting a trigger role for COVID-19 infection in autoimmune induced CNS disorders.

Based on the reviewed articles in this study, limbic encephalitis is the most frequent type of encephalitis among patients with AE, followed by anti-NMDA receptor encephalitis. This type of encephalitis is caused by autoantibodies that target NMDA receptors located in CNS.

Infection-induced anti-NMDA-R encephalitis has been reported after herpes simplex virus (HSV1) infection (18) . In a prospective study, AE was observed in about 27% of patients with However, antibody test could be negative in some patients (38) . Studies have reported that corticosteroids and intravenous immunoglobulin are considered as first-line therapies for AE treatment (15, (38) (39) (40) .

Our systematic review revealed evidence on the probability of developing AE in patients infected with the COVID-19. Clinicians should be aware of the possible diagnosis of AE when considering other neurological differential diagnosis in SARS-CoV-2 infected patients.

The authors declare there is no conflict of interest 

Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Emerging coronaviruses: Genome structure, replication, and pathogenesis

Neurological manifestations temporally associated with SARS-CoV-2 infection in pediatric patients in Mexico. Child's nervous system

New-Onset Seizure With Possible Limbic Encephalitis in a Patient With COVID-19 Infection: A Case Report and Review

Guillain-Barré Syndrome Associated with SARS-CoV-2

Autoimmune haemolytic anaemia associated with COVID-19 infection

Neurological manifestations of the coronavirus (SARS-CoV-2) pandemic 2019-2020

Neurologic Features in Severe SARS-CoV-2 Infection. The New England journal of medicine

Immune-mediated neurological syndromes in SARS-CoV-2-infected patients

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Possible Autoimmune Encephalitis with Claustrum Sign in case of Acute SARS-CoV-2 Infection

Steroid-Responsive Encephalitis in Coronavirus Disease

Psychosis in a patient with anti-NMDA-receptor antibodies experiencing significant stress related to COVID

Intravenous immunoglobulin response in new-onset refractory status epilepticus (NORSE) COVID-19 adult patients

Clinical Presentation and Outcomes of Severe Acute Respiratory Syndrome Coronavirus 2-Related Encephalitis: The ENCOVID Multicenter Study

New-onset refractory status epilepticus (NORSE) in post SARS-CoV-2 autoimmune encephalitis: a case report

Anti-NMDA receptor encephalitis presenting as new onset refractory status epilepticus in COVID-19

Autoimmune limbic encephalitis related to SARS-CoV-2 infection: Case-report and review of the literature. Brain, behavior, & immunity -health

Anti-NMDA receptor encephalitis in a psychiatric COVID-19 patient: A case report

A case of limbic encephalitis associated with asymptomatic COVID-19 infection

Postinfectious brainstem encephalitis associated with SARS-CoV-2

Neurological Disorders Associated With COVID-19 Hospital Admissions: Experience of a Single Tertiary Healthcare Center

Delirium as a presenting feature in COVID-19: Neuroinvasive infection or autoimmune encephalopathy?

N-Methyl-d-Aspartate Receptor Encephalitis Associated With COVID-19 Infection in a Toddler

Coronavirus disease 2019 associated with aggressive neurological and mental abnormalities confirmed based on cerebrospinal fluid antibodies: A case report

Autoimmune Encephalitis Concomitant with SARS-CoV-2 Infection: Insight from (18)F-FDG PET Imaging and Neuronal Autoantibodies

COVID-19-Associated Neurological Disorders: The Potential Route of CNS Invasion and Blood-Brain Relevance

Neuroinvasion and inflammation in viral central nervous system infections

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

Distinct intrathecal interleukin-17/interleukin-6 activation in anti-N-methyl-d-aspartate receptor encephalitis

Neurological manifestations temporally associated with SARS-CoV-2 infection in pediatric patients in Mexico

Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis

Possible autoimmune encephalitis with claustrum sign in case of acute SARS-CoV-2 infection

A case of limbic encephalitis associated with asymptomatic COVID-19 infection

Neuropathology of patients with COVID-19 in Germany: a post-mortem case series

Coronavirus disease 2019 associated with aggressive neurological and mental abnormalities confirmed based on cerebrospinal fluid antibodies: A case report

Postinfectious brainstem encephalitis associated with SARS-CoV-2

Steroidresponsive encephalitis in coronavirus disease 2019

Autoimmune encephalitis concomitant with SARS-CoV-2 infection: insight from 18F-FDG PET imaging and neuronal autoantibodies